Eloxx Pharmaceuticals (ELOX) vs Pelthos Therapeutics (PTHS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Pelthos Therapeutics is the larger company by market cap ($78.5 million vs $55.5 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ELOX | PTHS |
|---|---|---|
| Share price | $13.74 | $20.50 |
| Market cap | $55.46M | $78.48M |
| 1-day change | -9.49% | 0.00% |
| YTD return | — | -33.87% |
| 1-year return | — | -18.00% |
| P/E ratio (TTM) | 3.90 | — |
| EPS (TTM) | $3.52 | $-27.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $23.40 | $37.50 |
| 52-week low | $8.20 | $18.19 |
| Distance from 52-week high | -41.28% | -45.33% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +178.38% | +159.22% |
| Average volume | 44.52K | 60.55K |
| Shares outstanding | 4.04M | 3.83M |
| Employees | 10 | 92 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Eloxx Pharmaceuticals
ELOX stock →Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with nonsense mutations, and nephropathic cystinosis with nonsense mutations, as well as in a preclinical stage for the treatment of autosomal dominant polycystic kidney disease with nonsense mutations.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 10 employees
About Pelthos Therapeutics
PTHS stock →Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 92 employees
ELOX vs PTHS FAQ
Which is bigger, Eloxx Pharmaceuticals or Pelthos Therapeutics?
Pelthos Therapeutics (PTHS) is larger, with a market capitalization of $78.48M compared with $55.46M for Eloxx Pharmaceuticals (ELOX).
Are Eloxx Pharmaceuticals and Pelthos Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.